Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. Eads, J., Catalano, P. J., Fisher, G. A., Rubin, D., Iagaru, A., Klimstra, D. S., Konda, B., Kwong, M. S., Chan, J. A., De Jesus-Acosta, A., Halfdanarson, T., Shaib, W., Soares, H. P., Hong, S., Wong, T. Z., O'Dwyer, P. J. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301186